12.56 0.00 (0.00%)
After hours: 4:39PM EDT
|Bid||12.53 x 1200|
|Ask||12.62 x 800|
|Day's Range||12.36 - 12.59|
|52 Week Range||12.30 - 19.84|
|Beta (3Y Monthly)||0.35|
|PE Ratio (TTM)||20.93|
|Earnings Date||Apr 30, 2019|
|Forward Dividend & Yield||0.50 (2.84%)|
|1y Target Est||13.33|
Does the April share price for Meridian Bioscience, Inc. (NASDAQ:VIVO) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by projecting its future cash flows and then discounting them to today's val...
CINCINNATI, April 18, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced the launch of its Inhibitor-tolerant qPCR Mix, a novel mix to accelerate workflows and.
MedMen Announces Preliminary Q3 Revenues(Continued from Prior Part)Valuation multipleSince the beginning of 2019, MedMen Enterprises (MMEN) (MMNFF) has fallen by 3.6% as of April 12. The decline in MedMen’s stock price has also lowered its
MedMen Announces Preliminary Q3 RevenuesThird-quarter performance Today, MedMen Enterprises (MMEN) (MMNFF) posted an unaudited revenue of $36.60 million for the third quarter of fiscal 2019, which ended on March 30, 2019. Year-over-year, the
CINCINNATI, April 10, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials will report second quarter.
Meridian Bioscience, Inc. (VIVO), a provider of diagnostic testing solutions and life science raw materials, today provided a business update including preliminary sales results for its second fiscal quarter and revised financial guidance for fiscal 2019. The Company expects second fiscal quarter 2019 revenues to be approximately $50.0 million, compared to $56.5 million in the second fiscal quarter of 2018. This decline is being driven by Diagnostics segment revenues, which are expected to be down approximately 14% to 16% for the quarter, and relatively flat revenues for the Life Science segment compared to the second fiscal quarter of 2018.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Two important questions to ask before you buy Meridian Bioscience, Inc. (NASDAQ:VIVO) is, how it makes money and how it spend...
VIVO Cannabis Launches New Integrated Medical Cannabis WebsiteThe announcementThrough its wholly owned subsidiary, Canna Farms Limited, VIVO Cannabis (VIVO) launched an integrated Canna Farms medical cannabis website today. The platform is expected
TGOD’s Hamilton Facility Receives Organic CertificationThe announcementToday, The Green Organic Dutchman Holdings (TGOD)(TGODF) announced that its cultivation facility in Hamilton received organic certification from Pro-cert Organic Systems, a
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be remiss not to mention that insider sales haveRead More...
CINCINNATI, Feb. 07, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced that following the successful release of the Lyo-Ready qPCR Mix, Meridian is proud to.
NEW YORK, Feb. 04, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
VIVO Cannabis and Trulieve Posted Strong Performance Last WeekCannabis sector performanceLast week cannabis stocks performed well due to strength in the broader equity market with the S&P 500 Index rising by 1.6%. From January 25 to February 1,
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 11.11% and -0.04%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cincinnati-based company said it had profit of 19 cents per share. Earnings, adjusted for non-recurring costs, were 20 cents per share. The results surpassed Wall Street expectations. The average estimate ...
CINCINNATI, Jan. 24, 2019 -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the first quarter ended December 31, 2018. First Quarter 2019.
Building up an investment case requires looking at a stock holistically. Today I've chosen to put the spotlight on Meridian Bioscience, Inc. (NASDAQ:VIVO) due to its excellent fundamentals in more Read More...
Ericsson (ERIC) is likely to report higher year-over-year revenues in the fourth quarter of 2018 on the back of healthy growth dynamics.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech Stocks Hitting 52-week highs on Jan. 7) Axsome Therapeutics Inc (NASDAQ: AXSM ) ( reported positive ...